• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Crit Care Explor . The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Pa

tetano

Editor, Senior Moderator
Crit Care Explor


. 2020 Jun 15;2(6):e0145.
doi: 10.1097/CCE.0000000000000145. eCollection 2020 Jun.
The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases


Munir E Hazbun[SUP] 1 2 [/SUP], Andrew C Faust[SUP] 3 [/SUP], Anthony L Ortegon[SUP] 1 2 [/SUP], Lyndsay A Sheperd[SUP] 3 [/SUP], Gary L Weinstein[SUP] 1 2 [/SUP], Rebecca L Doebele[SUP] 1 2 [/SUP], Kenney D Weinmeister[SUP] 1 2 [/SUP], Allison M Liddell[SUP] 4 5 [/SUP], Mark Feldman[SUP] 6 7 [/SUP]



Affiliations

Abstract

Objective: To describe the outcomes with use of a combination of tocilizumab and methylprednisolone administered around the time of endotracheal intubation in patients with confirmed coronavirus disease 2019-associated hypoxemic respiratory failure requiring mechanical ventilation.
Data sources: Retrospective chart review.
Study selection/data extraction: Twenty-one consecutive patients with confirmed coronavirus disease 2019-associated hypoxemic respiratory failure requiring mechanical ventilation. Initial ventilator parameters were positive end-expiratory pressure 14 cm H[SUB]2[/SUB]o and target plateau pressure 29 cm H[SUB]2[/SUB]o to maximize lung recruitment. Methylprednisolone (125 mg every 6hr for 24 hr with tapering to 60 mg every 12 hr) was administered shortly after patients were intubated (median 11 hr after intubation).
Data synthesis: No patient in the cohort died while hospitalized (mortality, 0%; 95% CI, 0%-18%) and 18 patients have been discharged from the acute care setting. Twenty of 21 patients (95%) have been liberated from mechanical ventilation after a median duration of 8 days (range, 4-30 d). Following 48 hours of methylprednisolone, the A-a o[SUB]2[/SUB] gradient decreased from 455 ? 103 to 228 ? 109 mm Hg (difference 227 ? 108 mm Hg; p < 0.01).
Conclusions: Our positive experience with tocilizumab in combination with methylprednisolone started early after endotracheal intubation may be one avenue for reducing the morbidity and mortality seen with severe coronavirus disease 2019 and merits further exploration in clinical studies.

Keywords: artificial respiration; coronavirus disease 2019; cytokine release syndrome; glucocorticoids; respiratory distress syndrome; viral pneumonia.
 
Back
Top Bottom